Prostate Epidemiology Forecast

$ 9.590,00

Prostate Epidemiology Forecast

Prostate cancer is the most common men cancer detected in mature countries, and the second leading cause of cancer death. The prostate cancer is classified as ICD-9-CM category 185.

  • Countries concerned :

Add to my wishlist

In the G7 mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK), Hoffmann-Krueger epidemiologists expect the incident cases of prostate cancer to increase from 462 307 cases in 2012 to 560 640 cases in 2022.

 

Scope: G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)

10-year patient population forecast + 5 years of historical data

 

Key Users:  Oncology Market Research - New Product Planning - Business Development & Licensing

Oncology Market Access – Oncology Marketing leaders

 

Insight: Insight into the prostate cancer strategy and business development activities

Transparent forecasts methodology and assumptions

Concise and comparable analysis

 

Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.

 

The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.

 

Reasons To Buy

 

Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

  • Country : Japan | Germany | United States | Spain | Italy | France | United Kingdom
  • Cancer Type : Prostate C
  • File : xls